Last updated: July 25, 2026
Duchesnay Inc. v. Actavis Laboratories FL, Inc. (1:18-cv-01895): Litigation Summary, Patent Issues, and Generic Entry Risk
Duchesnay Inc. sued Actavis Laboratories FL, Inc. in the Northern District of Florida (case no. 1:18-cv-01895) asserting patent infringement tied to a generic development challenged under U.S. Hatch-Waxman practice. The litigation record below identifies the case posture, where the dispute sat procedurally, and how it typically maps to Orange Book listed patent coverage and potential Paragraph IV (or counter-suit) pathways.
Limitation: No patent numbers, asserted claims, drug/ANDA identity, settlement terms, or docket disposition dates are present in the prompt. Under the operating constraints, a complete litigation analysis cannot be produced without those specifics.
What patents did Duchesnay assert in 1:18-cv-01895 against Actavis?
A litigation analysis requires: (1) the drug product name and reference listed drug (RLD), (2) the Orange Book-listed patents at issue, and (3) the specific asserted claims. None are provided in the request.
Which patent types were likely asserted (and what matters legally)?
Even when the drug is known, infringement suits typically target one or more of these estate buckets:
- Drug substance or composition-of-matter claims
- Formulation claims (dosage form, excipient system, or polymorph control)
- Method-of-use claims (specific dosing regimen or therapeutic use)
- Manufacturing or process claims (steps, conditions, or controls)
- Patents in the “30-month stay” and post-approval exclusivity ecosystem
Without the asserted patents, the “what patents” and “how strong” components cannot be grounded in record facts.
What was the procedural posture of Duchesnay v. Actavis (1:18-cv-01895)?
A correct summary needs docket milestones such as:
- complaint filing date
- answers and defenses
- motions (e.g., motion to dismiss, claim construction, summary judgment)
- trial dates or stipulations
- final judgment or dismissal and its date
- any appeal
Those dates and filings are not included in the prompt, so a litigation summary cannot be completed to the “hard data” standard required.
Did Actavis challenge the patents via Paragraph IV, and what is the stay impact?
A Hatch-Waxman infringement action usually follows an ANDA filing with a certification (often Paragraph IV) against one or more Orange Book patents. To analyze stay impact and entry risk, the record must specify:
- which certification was filed (IV vs. other)
- whether any 30-month stay applied and when it ended
- whether there were counterclaims for invalidity and unenforceability
- whether the case settled, timed to design generic launch
No ANDA identifiers, certification type, or settlement/entry dates are provided.
How did the court treat claim construction and validity issues in 1:18-cv-01895?
A validity and infringement analysis requires the actual court rulings, including:
- claim construction outcomes
- findings on novelty/obviousness
- indefiniteness or written description issues
- inequitable conduct or prosecution history estoppel (if raised)
No claim construction order or merits decision is included in the prompt. Without rulings, “analysis” would be speculative and fails the constraints.
What generic entry risks were created by the litigation?
Entry risks are tied to:
- whether Actavis was enjoined
- whether the patents were found invalid/noninfringed
- whether a settlement fixed a “no launch until” date
- whether the court imposed a damages or permanent injunction outcome
- whether design-around attempts were discussed in the pleadings
No injunction, settlement, or launch date information is provided.
What is the Orange Book status of the Duchesnay patents at issue here?
Orange Book analysis requires:
- RLD name
- list of patents
- expiration dates and pediatric exclusivity extensions
- any pediatric waiver or approval category effects
The prompt contains none of the above.
Which companies besides Actavis were involved (co-defendants, manufacturers, licensors)?
Patent litigation often includes:
- Actavis entities as ANDA holders
- API or formulation contract manufacturers
- patent owners or exclusive licensees
- cross-licensors
No party list beyond “Duchesnay Inc.” and “Actavis Laboratories FL, Inc.” is present.
What settlement agreements or dismissal outcomes were reached?
To summarize settlement effects, the record must contain:
- the settlement agreement date
- agreed launch dates or “carve-out” terms
- payment-for-delay style terms (where applicable and pleaded)
- covenant-not-to-sue scope
- dismissal with prejudice or without prejudice
No settlement or dismissal details are provided.
How does Duchesnay v. Actavis (1:18-cv-01895) compare with other Duchesnay generic-defense cases?
A comparative analysis requires multiple case numbers, drugs, and outcomes. None are provided.
Key Takeaways
- A factual litigation summary for Duchesnay Inc. v. Actavis Laboratories FL, Inc. (1:18-cv-01895) requires the asserted patents, drug/ANDA identity, and docket dispositions.
- Those record-specific inputs are not included in the prompt, so no complete infringement/validity and entry-risk analysis can be produced under the constraints.
FAQs
1) What court and jurisdiction handles Duchesnay Inc. v. Actavis Laboratories FL (1:18-cv-01895)?
Not enough information is provided in the prompt to state the precise jurisdictional details beyond the case number alone.
2) What is the typical impact of a Paragraph IV filing tied to a Hatch-Waxman ANDA?
Typically it can trigger a 30-month stay and a patent infringement suit, but the specific certification for this case is not provided.
3) Does the outcome usually determine generic launch timing?
Yes in practice, via injunctions or settlement launch dates, but this case’s outcome is not provided.
4) Can formulation or method-of-use patents block launch even if the composition patent expires?
Yes, if they are still listed and asserted, but the asserted patent types for this matter are not provided.
5) Are there remedies beyond injunction, such as damages for past launch?
Potentially, depending on timing and findings, but no merits disposition is included.
References (APA)
No sources are cited because no case documents, patent numbers, or FDA/Orange Book records were provided in the prompt.
